ABCL Strangle Strategy
ABCL (AbCellera Biologics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL (AbCellera Biologics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.25B, a beta of 1.20 versus the broader market, a 52-week range of 2.745-7.4, average daily share volume of 7.0M, a public-listing history dating back to 2020, approximately 596 full-time employees. These structural characteristics shape how ABCL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.20 places ABCL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on ABCL?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ABCL snapshot
As of June 30, 2026, spot at $7.89, ATM IV 110.90%, IV rank 19.13%, expected move 31.79%. The strangle on ABCL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on ABCL specifically: ABCL IV at 110.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a ABCL strangle, with a market-implied 1-standard-deviation move of approximately 31.79% (roughly $2.51 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABCL expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABCL should anchor to the underlying notional of $7.89 per share and to the trader's directional view on ABCL stock.
ABCL strangle setup
The ABCL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABCL near $7.89, the first option leg uses a $8.28 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABCL chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABCL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $8.28 | N/A |
| Buy 1 | Put | $7.50 | N/A |
ABCL strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ABCL strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ABCL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ABCL
Strangles on ABCL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABCL chain.
ABCL thesis for this strangle
The market-implied 1-standard-deviation range for ABCL extends from approximately $5.38 on the downside to $10.40 on the upside. A ABCL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ABCL IV rank near 19.13% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ABCL at 110.90%. As a Healthcare name, ABCL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABCL-specific events.
ABCL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABCL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABCL alongside the broader basket even when ABCL-specific fundamentals are unchanged. Always rebuild the position from current ABCL chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ABCL?
- A strangle on ABCL is the strangle strategy applied to ABCL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ABCL stock trading near $7.89, the strikes shown on this page are snapped to the nearest listed ABCL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABCL strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABCL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 110.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABCL strangle?
- The breakeven for the ABCL strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABCL market-implied 1-standard-deviation expected move is approximately 31.79%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ABCL?
- Strangles on ABCL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABCL chain.
- How does current ABCL implied volatility affect this strangle?
- ABCL ATM IV is at 110.90% with IV rank near 19.13%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.